Aruhan Yang1, Xiaoxue Zhu1, Lei Zhang2, Yingwen Zhang3, Dezhi Zhang4, Meishan Jin4, Junqi Niu3, Huimao Zhang2, Yanhua Ding5, Guoyue Lv6. 1. Phase I Clinical Trial Unit, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China. 2. Department of Radiology, First Hospital of Jilin University, Changchun, China. 3. Department of Hepatology, First Hospital of Jilin University, Changchun, China. 4. Department of Pathology, First Hospital of Jilin University, Changchun, China. 5. Phase I Clinical Trial Unit, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China. dingyanh@jlu.edu.cn. 6. Department of Hepatobiliary and Pancreatic Surgery, First Hospital of Jilin University, No. 71 Xinmin Street, Changchun, 130021, Jilin, China. lvgy@jlu.edu.cn.
Abstract
OBJECTIVE: To investigate the clinical, laboratory and genetic features of NAFLD patients based on MRI-PDFF in China. DESIGN: Patients with high ALT and with a diagnosis of fatty liver were included in this cross-sectional study. Fasting blood was collected to test biomarkers and SNPs. A total of 266 patients underwent MRI-PDFF and FibroScan examinations, and 38 underwent liver biopsy. Diagnostic models (decision tree, LASSO, and elastic net) were developed based on the diagnosis from MRI-PDFF reports. RESULTS: Approximately, 1/3 of the patients were found to have NASH and fibrosis. After quantifying liver steatosis by MRI-PDFF (healthy: n = 47; mild NAFLD: n = 136; moderate/severe NAFLD: n = 83; liver fat content (LFC): 3.6% vs. 8.7% vs. 19.0%), most biomarkers showed significant differences among the three groups, and patients without obesity were found to have a similar LFC as those with obesity (11.1% vs. 12.3%). Models including biomarkers showed strong diagnostic ability (accuracy: 0.80-0.91). Variant alleles of PNPLA3, HSD17B13 and MBOAT7 were identified as genetic risk factors causing higher LFC (8.7% vs. 12.3%; 11.0% vs. 14.5%; 8.5% vs. 10.2%, p < 0.05); those with the UQCC1 rs878639 variant allele showed lower LFC (10.4% vs. 8.4%; OR = 0.58, p < 0.05). Patients with more risk alleles had higher LFCs (8.1% vs. 10.7% vs. 11.6% vs. 14.5%). CONCLUSIONS: Based on MRI-PDFF, a combination of several specific biomarkers can accurately predict disease status. When the effects of genes on liver steatosis were first quantified by MRI-PDFF, the UQCC1 rs878639 G allele was identified as a protective factor, and the MBOAT7 T allele was identified as a risk only among nonobese individuals.
OBJECTIVE: To investigate the clinical, laboratory and genetic features of NAFLD patients based on MRI-PDFF in China. DESIGN: Patients with high ALT and with a diagnosis of fatty liver were included in this cross-sectional study. Fasting blood was collected to test biomarkers and SNPs. A total of 266 patients underwent MRI-PDFF and FibroScan examinations, and 38 underwent liver biopsy. Diagnostic models (decision tree, LASSO, and elastic net) were developed based on the diagnosis from MRI-PDFF reports. RESULTS: Approximately, 1/3 of the patients were found to have NASH and fibrosis. After quantifying liver steatosis by MRI-PDFF (healthy: n = 47; mild NAFLD: n = 136; moderate/severe NAFLD: n = 83; liver fat content (LFC): 3.6% vs. 8.7% vs. 19.0%), most biomarkers showed significant differences among the three groups, and patients without obesity were found to have a similar LFC as those with obesity (11.1% vs. 12.3%). Models including biomarkers showed strong diagnostic ability (accuracy: 0.80-0.91). Variant alleles of PNPLA3, HSD17B13 and MBOAT7 were identified as genetic risk factors causing higher LFC (8.7% vs. 12.3%; 11.0% vs. 14.5%; 8.5% vs. 10.2%, p < 0.05); those with the UQCC1 rs878639 variant allele showed lower LFC (10.4% vs. 8.4%; OR = 0.58, p < 0.05). Patients with more risk alleles had higher LFCs (8.1% vs. 10.7% vs. 11.6% vs. 14.5%). CONCLUSIONS: Based on MRI-PDFF, a combination of several specific biomarkers can accurately predict disease status. When the effects of genes on liver steatosis were first quantified by MRI-PDFF, the UQCC1 rs878639 G allele was identified as a protective factor, and the MBOAT7 T allele was identified as a risk only among nonobese individuals.
Authors: Beth A Davison; Stephen A Harrison; Gad Cotter; Naim Alkhouri; Arun Sanyal; Christopher Edwards; Jerry R Colca; Julie Iwashita; Gary G Koch; Howard C Dittrich Journal: J Hepatol Date: 2020-06-28 Impact factor: 25.083
Authors: Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; Jeremy Lok Wei; Grace Lai-Hung Wong; Anthony Wing-Hung Chan; Paul Cheung-Lung Choi; Sally She-Ting Shu; Angel Mei-Ling Chim; Henry Lik-Yuen Chan; Vincent Wai-Sun Wong Journal: Hepatology Date: 2016-07-25 Impact factor: 17.425